imatinib mesylate has been researched along with Spinal Cord Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruckner, JD; Conrad, EU; Eary, JF; Mirza, S; Norwood, TH; Rubin, BP; Schuetze, SM | 1 |
| Egorin, M; Ilaria, RL; Richardson, JA; Wolff, NC | 1 |
| Dieckmann, K; Fakhrai, N; Hainfellner, J; Marosi, C; Nemeth, A; Neophytou, P; Prayer, D | 1 |
3 other study(ies) available for imatinib mesylate and Spinal Cord Neoplasms
| Article | Year |
|---|---|
Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.
Topics: Adult; Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Humans; Imatinib Mesylate; Male; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Radionuclide Imaging; Skin Neoplasms; Spinal Cord Neoplasms | 2002 |
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Topics: Animals; Benzamides; Blood-Brain Barrier; Bone Marrow; Brain Neoplasms; Central Nervous System Diseases; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperazines; Pyrimidines; Spinal Cord Neoplasms; Transfection | 2003 |
Recurrent spinal ependymoma showing partial remission under Imatimib.
Topics: Adult; Antineoplastic Agents; Benzamides; Ependymoma; Female; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Spinal Cord Neoplasms | 2004 |